Asset 1@3x.png

Pioneering the development of novel

immuno-oncology and immune therapies

Our Team

The HaemaLogiX team is researching immune-based treatments that target unique antigens on malignant cells to improve the quality of life of patients suffering from blood cancers.

Asset3@3x.png
Asset 4@3x.png

Our Pipeline

Our research platform involves multiple approaches in treating Multiple Myeloma – a blood cancer, and AL Amyloidosis – a life-threatening abnormal protein build-up in tissues and organs.

Our Innovation

Following the discovery of two unique antigens on malignant Bone Marrow Cells, we are developing Monoclonal Antibodies, CAR T cell Therapies and Bispecific Antibodies that specifically target those malignant cells.

car-t ell.png

News & Events

HaemaLogiX welcomes Tertia Dex to the team

17 Jan 2022

HaemaLogiX welcomes Professor Simon Harrison to the SAB

21 Dec 2021

Full presentation materials on the novel antigens LMA and KMA at the 63rd annual ASH meeting are now available

15 Dec 2021